Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Liu D, Shoag JE, Poliak D, Goueli RS, Ravikumar V, Redmond D, et al. Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes. Nat Commun. 2020;11(1):1987.

G Park K, Lee JH, Soriano E, Choi M, Bao K, Katagiri W, et al. Rapid and Selective Targeting of Heterogeneous Pancreatic Neuroendocrine Tumors. iScience. 2020;23(4):101006.

Sadick N, Magro C. Response to Letter to the Editor. J Am Acad Dermatol. 2020.

Adams EJ, Karthaus WR, Hoover E, Liu D, Gruet A, Zhang Z, et al. Author Correction: FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. 2020;585(7826):E20.

Muldoon JL, Wysozan TR, Toubin Y, Relich RF, Davis TE, Zhang C, et al. An unusual presentation of cutaneous histoplasmosis as a recurrent solitary and spontaneously healing lesion in an immunocompetent patient. Access Microbiol. 2020;2(9):acmi000156.

Dillard A, DeSimone RA, Hsu Y-, Ma L, Vasovic L, Racine-Brzostek S, et al. Flat line in the blood bank: code H (hyperfibrinolysis)? Transfusion. 2020;60(9):1894-1896.

Shi CY, Kingston ER, Kleaveland B, Lin DH, Stubna MW, Bartel DP. The ZSWIM8 ubiquitin ligase mediates target-directed microRNA degradation. Science. 2020;370(6523).

Patel SS, Weinberg OK. Diagnostic workup of acute leukemias of ambiguous lineage. Am J Hematol. 2020;95(6):718-722.

Cushing MM, Haas T, Karkouti K, Callum J. Which is the preferred blood product for fibrinogen replacement in the bleeding patient with acquired hypofibrinogenemia-cryoprecipitate or fibrinogen concentrate? Transfusion. 2020;60 Suppl 3:S17-S23.

Petroni G, Formenti SC, Chen-Kiang S, Galluzzi L. Immunomodulation by anticancer cell cycle inhibitors. Nat Rev Immunol. 2020;20(11):669-679.